

Accepted Manuscript

Ruptured mycotic aneurysm after intravesical instillation for bladder tumor

Raffaella Berchiolli, Davide M. Mocellin, Michele Marconi, Francesca Tomei, Irene Bargellini, Roberta Zanca, Paola Erba, Mauro Ferrari



PII: S0890-5096(19)30178-5

DOI: <https://doi.org/10.1016/j.avsg.2018.12.100>

Reference: AVSG 4290

To appear in: *Annals of Vascular Surgery*

Received Date: 24 November 2018

Revised Date: 14 December 2018

Accepted Date: 15 December 2018

Please cite this article as: Berchiolli R, Mocellin DM, Marconi M, Tomei F, Bargellini I, Zanca R, Erba P, Ferrari M, Ruptured mycotic aneurysm after intravesical instillation for bladder tumor, *Annals of Vascular Surgery* (2019), doi: <https://doi.org/10.1016/j.avsg.2018.12.100>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Ruptured mycotic aneurysm after intravesical instillation for bladder tumor**

2 *Authors:*

3 Raffaella Berchioli¹,

4 Davide M. Mocellin¹,

5 Michele Marconi¹,

6 Francesca Tomei¹,

7 Irene Bargellini²,

8 Roberta Zanca²,

9 Paola Erba³,

10 Mauro Ferrari³,

11 ¹ Vascular Surgery Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

12 ² Interventional Radiology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

13 ³ Nuclear Medicine, Department of Translational Research and New Technology in Medicine,
14 University of Pisa, Pisa, Italy

15

16 *Corresponding author:*

17 Michele Marconi.

18 E-mail: michemarconi@gmail.com

19 Vascular Surgery Unit, Azienda Ospedaliero Universitaria Pisana.

20 Via Paradisa, 2. Pisa. 56124. Italy.

21 Phone number 00393287648533

22

23 **Abstract**

24 **Introduction** Intravesical instillation of Bacillus Calmette-Guérin (BCG) is an effective, widely
25 used treatment for patient affected by in-situ bladder cancer. Major complications are quite
26 uncommon, but a systemic dissemination of the attenuated strain of Mycobacterium bovis (MB) is
27 possible. Few cases of aortic rupture caused by M. bovis infection are described in Literature.

28 **Case report** A 70-year-old male, treated three months before with BCG instillation, presented to
29 the emergency department because of a ruptured abdominal aortic aneurysm. Patient was
30 hemodynamically stable, with a “hostile” abdomen. Thus, an Endologix AFX endograft was
31 deployed. During post-operative period, blood inflammatory markers increased, suspicious for the
32 presence of infection. SPECT/CT scan showed aortic increased uptake at the site of the aortic
33 aneurysm. Antibiotic therapy was continued but, some days after, patient presented hematemesis
34 and CT scan showed an aorto-enteric fistula. In emergency, the infected graft and aneurysm were
35 removed, enteric fistula closed and an axillo-bifemoral bypass performed. Patient died 25 days after
36 EVAR explant.

37 **Discussion** Despite the high suspicion of mycotic aortic aneurysm and graft infection by MB, there
38 is no proof of this theory cause of absence of any positive culture test. MB is a slow growing
39 bacteria and specific culture tests are required in order to identify it; indeed, all our blood and
40 intraoperative samples were positive to other bacteria, probably contaminant ones.

41 **Conclusions** Mycotic aneurysm is an extremely rare complication of intravesical BCG therapy, but
42 it must be taken into consideration in patients with rapidly growing aortic aneurysms or rupture of a
43 normal aorta, who have been previously submitted to this kind of instillation.

44

45 **Keywords:** mycotic aneurysm, intravesical administration, endovascular procedures

46

47 **Introduction**

48 Bacillus Calmette-Guérin (BCG) is a live attenuated strain of *Mycobacterium bovis* (MB), part of
49 *Mycobacterium Tuberculosis* complex, and it is an effective treatment for patients with stage T1
50 grade 3 bladder tumors, when applied topically by intravesical instillation. The instillation causes a
51 local inflammatory reaction that can destroy non-muscle invasive cancer cells. Despite it being an
52 effective and non-invasive treatment, it is not risk-free. The complication rate of this therapy is very
53 low, but few cases of systemic infection and multi-organ bacteria dissemination have been reported
54 [1]. One of the most dangerous infection sites is the abdominal aorta where *Mycobacterium*
55 proliferation can create a weakening of the arterial wall with a progressive but fast dilation of the
56 aorta up to its spontaneous rupture [1].

57 **Case report**

58 A 70-year-old male, affected by hypertension, hyperlipidemia and ischemic heart disease, presented
59 to the emergency department with a history of lumbar pain radiating bilaterally to the back lasting
60 from about one week. Patient history showed subsequent transurethral resections (10 and 5 months
61 before) and intravesical BCG therapy (3 months before) as treatment for bladder transitional cell
62 carcinoma. Two months apart, due to biopsy proven residual high degree transitional papillary cell
63 carcinoma, the patient was subsequently treated with robot-assisted radical cystectomy followed by
64 urostomy.

65
66 Abdominal computed tomographic (CT) scan was performed, revealing a ruptured abdominal aortic
67 aneurysm (RAAA) greater than 45mm in size (Figure 1). The patient was hemodynamically stable.

68 Due to the “hostile” abdomen and the favorable anatomy, the patient was submitted to endovascular
69 aneurysm repair (EVAR) (BA25-90/120-30 AFX, Endologix Inc., Irvine, CA, USA) through a
70 bilateral groin cutdown approach. After surgery the patient was transferred to the Vascular Surgery
71 ward. The comparative assessment of a previous CT scan which has been performed at the time of
72 the radical cystectomy and which was not available at the time of emergency admission revealed a

73 normal aorta (Figure 2). The referring urologist excluded the possibility of aortic iatrogenic lesions
74 during the pelvic lymphadenectomy.

75 After an initial postoperative period with complete pain relief, blood tests showed a progressive
76 increase of inflammatory markers (white blood cells increased from 9450/ μ L to 17180/ μ L and C-
77 reactive protein from 3.34 mg/dl to 15.9 mg/dl) in absence of fever. Positive blood and urine
78 cultures for *Staphylococcus aureus* were found; therefore according to the drug susceptibility
79 profile, antibiotic therapy with cefazolin (2gr intravenous four times a day) was initiated due to
80 clinical suspicious of graft infection. 99m Tc-HMPAO-WBC SPECT/CT was performed, revealing a
81 significant radiopharmaceutical uptake at the level of abdominal aorta, suggesting infection (Figure
82 3). After few days, new onset of fever and abdominal pain occurred with significant increase of
83 WBC counts. Ten days after the surgery, patient presented hematemesis and hemodynamic shock.
84 Urgent CT scan revealed free air bubbles in the abdomen, thus suspecting the presence of aorto-
85 enteric fistula (Figure 4). Urgent laparotomy was performed confirming the aorto-enteric fistula at
86 the level of duodenum with the exposition of the endograft (Figure 5). After suprarenal clamping,
87 the endograft was easily removed due to its characteristics (no proximal hook and anatomical
88 fixation) and sent for culture (Figure 6). Because of the evident signs of infection, the proximal
89 aortic stump was sutured just below the origin of renal arteries with a double layer of 2/0 non-
90 absorbable sutures (PROLENE® Polypropylene Suture, Ethicon, Somerville, NJ, USA). Distally
91 the aorta was sutured at the level of its bifurcation. Proximal aortic stump was covered with a large
92 omental flap. The duodenum lesion was repaired with 3/0 absorbable suture (PDS® II,
93 polydioxanone suture, Ethicon, Somerville, NJ, USA). Finally, a left axillo-bifemoral bypass was
94 performed (Axillo-bifemoral Equi-flo Gelsoft, Vascutek Ltd, Scotland, UK).

95 The early postoperative period was complicated by critical colic ischemia, requiring total
96 colectomy. Graft, aortic wall and thrombus cultures were positive for *Enterococcus Faecium*,
97 *Saccaromices Celevisie*, *Candida Glabrata* and antimicrobial therapy was modified accordingly
98 (endovenous injection of fosfomycin 3gr/day, meropenem 1gr every 8 hour, daptomycin

99 700mg/day, and caspofungin 50mg/day). Interestingly, MB was not isolated because specific
100 examinations were not explicitly requested. Patient passed away 25 days after EVAR explant.

101

102 **Discussion**

103 Intravesical BCG instillation therapy is the treatment of choice for early stage transitional cell
104 bladder cancer with reported cure rates of 70% [2]. Although it is a well-tolerated treatment,
105 systemic reactions, such as fever, malaise, hepatitis and pneumonia have been described [2,3].
106 Vascular complications, such as mycotic aneurysms occur in less than 1% of cases [4]. In literature,
107 less than 30 cases of MB related mycotic aneurysms are reported [5,6]. The presence of mycotic
108 aneurysms, similarly to other complications of intravesical BCG therapy, is a late event appearing
109 up to five years after BCG instillation during patients' follow-up [6]. Fifty percent of mycotic
110 aneurysms secondary to BCG instillation ruptured and required emergency surgery [7-8].

111 However, considering the widespread utilization of BCG instillation for the treatment of early stage
112 bladder cancer, the incidence of mycotic aneurysms after BCG instillation may be currently
113 underestimated [9]. This might be related to the very difficult diagnosis due to the fact that
114 identification of MB requires specific culture and histological methods, such as polymerase chain
115 reaction (PCR) and focused coloration for bacterioscopic examination. As a matter of fact, in this
116 case report, suspicion of MB infection arised only after the last operation, when patient's clinical
117 history was deeply investigated and it was too late to request those specific exams. It would be
118 interesting to perform an autopsy to confirm our suspect, but patient's family refused it.

119 Once BCG mycotic aneurysms have been identified, well-defined guidelines for its management are
120 still lacking; the treatment can vary from a fully conservative choice to a partial or completely
121 surgical solution. The decision is normally tailored upon each single patient, with regards to his
122 health conditions. The "gold standard" is represented by the complete excision and the debridement
123 of infected tissues, followed by the restoration of the flow to the legs.

124 Conservative treatment presents the worse prognosis, it is reserved only to patients who are too
125 compromised to undergo a surgical operation and it is not viable in an emergency situation
126 associated to bleeding.

127 The best treatment in aortic graft infection is a surgical approach; it's a challenging process,
128 indicated in patients fit for it, but often inevitable in critical patients too.

129 In emergency, aortic complications (aorto-enteric fistula, aorto-esophageal/bronchial fistula or
130 ruptured pseudoaneurysm) can be managed first with an endovascular approach, directed to solve
131 the acute bleeding. This should be a "bridge" solution but, in some cases, endovascular solution,
132 associated to long-life antibiotic therapy, becomes the definitive treatment.

133 Surgical treatment is based on two principles: eradication of the infected tissue and maintenance of
134 vascular perfusion to lower limbs. To restore the perfusion, extra-anatomic bypasses or in-situ
135 reconstructions could be performed, by the use of antibiotic-soaked graft, autologous vein graft,
136 fresh allograft, cryopreserved allograft or neo-aortoiliac system reconstruction. Extra-anatomical
137 bypasses, such as axillo-bifemoral, allow to restore the perfusion to lower limbs by placing the new
138 conduit through a safe, not infected area but they have a high risk of occlusion and aortic stump
139 disruption. In situ reconstruction with silver or antibiotic impregnated graft is cheap and easy to
140 reach and to be available in emergency too, but it has still a high risk of reinfection. Reconstruction
141 of aortic bifurcation with autologous vein, like superficial femoral, is quit safe for what concern
142 patency and reinfection risk but it requires long operating times and accurate venous system study
143 before the intervention, difficult to obtain in emergency situations. Fresh and cryopreserved
144 allografts showed good results in preventing reinfection but they are susceptible to aneurysmal
145 degeneration (especially fresh ones) and are difficult available in emergency.

146 Harding et al. suggested performing an extra-anatomical bypass as a standard management of BCG-
147 related primary aortic infection [3]. In this case report, EVAR was performed because of recent
148 open abdominal surgery, the favorable aortic anatomy and the lack of evidence of possible
149 infectious etiology of the aneurysm. Antimicrobial treatment based on the isolated strain was not

150 successful in limiting the infection burden. In the hypothesis of the MB-etiology a specific
151 antitubercular therapy could have provided better results. However, since all the analyses performed
152 were not able to demonstrate the MB infection these are just hypothesis. Nonetheless, on the basis
153 of the patient's history, the rapidity of the aneurysm growth, and the clinical evolution with local
154 and systemic complications MB infection is highly suspected.

155

156 **Conclusion**

157 Mycotic aneurysm is an extremely rare but life-threatening complication of intravesical BCG
158 therapy. Despite its rarity, urologists and vascular surgeons should be aware of the risk of vascular
159 complications related to this therapy. An accurate and prompt diagnosis could address towards the
160 most adequate treatment.

161

162 **References**

- 163 1. Wolf YG, Wolf DG, Higginbottom PA, Dilley RB. Infection of a ruptured aortic aneurysm and
164 an aortic graft with bacille Calmette-Guérin after intravesical administration for bladder cancer. *J*
165 *Vasc Surg.* 1995;22:80-4.
- 166 2. Gao CQ, Mithani R, Leya J, Dawravoo L, Bhatia A, Antoine J, et al. Granulomatous hepatitis,
167 choroiditis and aortoduodenal fistula complicating intravesical bacillus Calmette-Guérin
168 therapy: case report. *BMC Infectious Diseases* 2011;11:260.
- 169 3. Hearing GEJ, Lawer DK. Ruptured mycotic abdominal aortic aneurysm secondary to
170 *Mycobacterium Bovis* after intravesical treatment with bacillus Calmette-Guérin. *J Vasc Surg*
171 2007; 46:131-4.
- 172 4. Pittman M, Sakai L, Craig R, Joehl R, Milner R. Primary aortoenteric fistula following
173 disseminated bacillus Calmette-Guérin infection: a case report. *Vascular.* 2012;20(4):221-4

- 174 5. Holmes BJ, LaRue RW, Black III JH, Dionne K, Parrish NM, Melia MT. Mycotic aortic
175 aneurysm due to intravesical BCG immunotherapy: Clinical manifestations and diagnostic
176 challenges. *Int J Mycob* 2014; 3:60-65.
- 177 6. Coddington ND, Sandberg JK, Yang C, Sehn JK, Kim EH, Strobe SA. Mycotic Aneurysm after
178 *Bacillus Calmette-Guérin* Treatment: Case Report and Review of the Literature. *Case Rep Urol*.
179 2017;2017:4508583
- 180 7. Roylance A, Mosley J, Jameel M, Sylvan A, Walker V. Aorto-enteric fistula developente
181 secondary to mycotic abdominal aortic aneurysm following intravesical bacillus Calmette-
182 Gierun (BCG) treatment for transitional cell carcinoma of the bladder. *Int J Surg case reports*
183 2013;4:88-90
- 184 8. Scarcello E, Ferrari M, Rossi G, Berchiolli R, Adami D, Romagnani F, et al. A new preoperative
185 predictor of outcome in ruptured abdominal aortic aneurysms: the time before shock (TBS). *Ann*
186 *Vasc Surg*. 2010 Apr;24(3):315-20.
- 187 9. Mizoguchi H, Iida O, Dohi T, Tomoda K, Kimura H, Inoue K, et al. Abdominal Aortic
188 aneurismal and endovascular device infection with iliopsoas abscess caused by *Mycobacterium*
189 *Bovis* as a complication of intravesical *Bacillus Calmette-Guèrin* therapy. *Ann Vasc Surg* 2013;
190 27: 1186.e1-1186.e5

191

192

193 **Figure legends**

194 **Figure 1** - CT angiography shows the presence of a ruptured infrarenal abdominal aortic 45 mm in
195 size.

196 **Figure 2** - CT angiography performed a few months before demonstrates that the abdominal aorta
197 is normal in size.

198 **Figure 3** - ^{99m}Tc-HMPAO WBC whole body images at 30 mins after the radiopharmaceutical
199 administration (A), planar spot view images in antero-posterior projection on the abdominal area
200 (B) at 30 mins (upper panel), 6 hrs. (middle panel) 20 hrs. (lower panel) and SPECT/CT (C, upper
201 panel coronal view from left to right emission, non-ceCT and superimposed SPECT/CT), trans axial
202 superimposed SPECT/CT at different level (C left), superimposed sagittal (C middle) and
203 superimposed coronal (C right) showing progressive increased radiopharmaceutical uptake at the
204 site of the aneurysm extending anteriorly to the contiguous bowel wall as clearly showed by the
205 SPECT/CT images. Of interest, despite endovascular repair of the abdominal aortic aneurysm
206 images was performed 4 days before the scintigraphy, no effect on the image quality was
207 determined and the image correctly identify the site and extend of infection.

208 **Figure 4** - CT angiography shows patency of the endograft, with air bubbles in the aneurysm sac
209 and an evidence of a large fistula between the aorta and the duodenum.


210 **Figure 5** - Intraoperative view of the aortoduodenal fistula.




ACCEPTED MANUSCRIPT




ACCEPTED



ACCEPTED MANUSCRIPT



ACCEPTED



ACC